Design therapeutics inc
DSGN 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
DSGN 近期報酬表現
0.53%
Design therapeutics inc
6.23%
同產業平均
1.02%
S&P500
與 DSGN 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
INSM | Insmed inc | 4 分 | 1 分 | 2 分 | 3 分 | 1 分 | |
XFOR | X4 pharmaceuticals inc | 3 分 | 5 分 | 3 分 | 1 分 | 1 分 | |
DNLI | Denali therapeutics inc | 4 分 | 1 分 | 2 分 | 3 分 | 1 分 | |
HLVX | Hillevax inc | - | 1 分 | 2 分 | 3 分 | 1 分 | |
RCKT | Rocket pharmaceuticals inc | 3 分 | 1 分 | 2 分 | 2 分 | 1 分 |
- INSM Insmed inc價值 4 分趨勢 1 分波段 2 分籌碼 3 分股利 1 分查看更多
DSGN 公司資訊
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.